Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume?

We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other top falling stocks with unusual volume.

Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons.

Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil.

To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity.

Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can’t ignore.

Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for its weight loss drugs Wegovy and Ozempic. These drugs continue to be the source of volatility in the stock, with the most recent example seen earlier this month.

Donald Trump’s government finalised some major decisions on medical care for older Americans, and weight loss drugs did not receive a favorable ruling. This lack of coverage caused a dip in the share prices of major weight loss drug developers, including Novo Nordisk A/S (NYSE:NVO).

Meanwhile, the company has no intention to slow down on its weight loss drug ambitions. A few days after the above bad news, it announced an investment of just over one billion dollars in Brazil in a bid to boost the production of both Wegovy and Ozempic. Brazil is a major manufacturing destination for the company, which exports its products to over 70 countries from the South American nation.

The stock is down 5.11% in a week on a relative volume of 3.72. A downtrend on high volumes suggests the price has room to drop further, so investors might be better off waiting on the sidelines before initiating a position in the stock.

Overall, NVO ranks 18th on our list of top falling stocks with unusual volume. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.